Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
Is there any reason to use GnRH agonists in patients with metastatic prostate cancer after bilateral orchiectomy?
Related Questions
What are your top takeaways from ASCO GU 2025?
Do you offer RT both to the prostate and synchronous oligometastases in de novo oligometastatic prostate cancer?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
Is there any evidence that ivermectin suppresses the PSA level in prostate cancer?
What are your top takeaways in GU Cancers from ESMO 2024?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
